MQ710 + Pembrolizumab for Solid Tumor Cancers

Recruiting in Palo Alto (17 mi)

+6 other locations

Overseen byLara Dunn, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Eligibility Criteria

This trial is for adults with advanced or metastatic solid tumor cancers that have relapsed, worsened after standard treatments, or have no standard treatment options. Eligible participants include those with specific skin cancers and head and neck squamous cell carcinoma who've failed previous therapies including anti-PD-1 therapy (except HNSCC patients with low PD-L1 expression). Participants must be in good enough health to comply with study procedures, not pregnant, willing to use contraception, and free from significant recent medical issues.

Inclusion Criteria

I have a specific type of skin cancer and standard treatments haven't worked for me.

Ability to comply with study procedures in the Investigator's opinion

I am 18 years old or older.

+18 more

Exclusion Criteria

I have a history of chronic liver disease or cirrhosis.

I have not had an uncontrolled infection in the last 6 months.

I had leukemia (ALL or CLL) or aggressive lymphoma but am in remission and not on immunosuppressive therapy.

+23 more

Participant Groups

The study aims to determine the highest dose of MQ710 that can be given safely alongside Pembrolizumab in people with various types of solid tumors. It will involve individuals whose cancer has returned at the original site or spread elsewhere and is resistant to conventional treatments or lacks such options.

2Treatment groups

Experimental Treatment

Group I: Dose Expansion GroupExperimental Treatment2 Interventions

MQ710 + pembrolizumab Approximately 8 patients will be recruited into the dose expansion group for monotherapy dosing of MQ710. Approximately 12 patients will be recruited for dosing at the MTD/maximally administered dose established in combination with pembrolizumab.

Group II: Dose Escalation GroupExperimental Treatment1 Intervention

MQ710 The dose levels will be escalated following a standard 3+3 dose escalation scheme.